BCTX News - Candlesense

BriaCell’s Bria-OTS+™ Mechanism of Action Validated in Highly Rated Peer Reviewed Cancer Journal

PHILADELPHIA and VANCOUVER, British Columbia, Aug. 26, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ), (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stag...

How does Bria-OTS+™ compare to competing off‑the‑shelf immunotherapies in terms of efficacy, differentiation, and market potential? What is the expected timeline for subsequent clinical trial milestones and potential regulatory approvals after this publication? How will the validation of Bria-OTS+™ in a high‑impact journal influence BCTX's short‑term stock price?

Clinical trials

about 9 hours ago

Read more globenewswire

BriaCell Awarded $2 Million NCI Grant to Advance Bria-PROS+™ in Prostate Cancer

PHILADELPHIA and VANCOUVER, British Columbia, Aug. 25, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ), (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stag...

How does Bria‑PROS+ compare to competing prostate‑cancer immunotherapies, and does this grant give BriaCell a competitive advantage? What is the anticipated timeline for clinical milestones of Bria‑PROS+ in prostate cancer, and how might those milestones affect the stock price? How will the $2 million NCI grant impact BriaCell’s cash runway and potential dilution for shareholders?

Funding

1 day ago

Read more globenewswire

BriaCell Announces Proposed Effective Date of Share Consolidation

PHILADELPHIA and VANCOUVER, British Columbia, Aug. 21, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage...

Will the consolidation improve BriaCell's ability to raise capital or affect its valuation relative to peers? What is the expected short‑term price reaction to the reverse split and could it trigger a technical bounce? How will the 1-for-10 share consolidation affect BriaCell's liquidity and trading volume on Nasdaq?

Corporate

5 days ago

Read more globenewswire

BriaCell Selected for MSK’s 2025 Therapeutics Accelerator Program for Bria-OTS+™ for Cancer

PHILADELPHIA and VANCOUVER, British Columbia, Aug. 13, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ), (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stag...

Are there any risks or contingencies disclosed that could delay or derail the clinical development of Bria‑OTS+? How might this news influence analyst coverage, target price revisions, or consensus estimates for BriaCell? Will the inclusion in the Accelerator program trigger any dilution from new equity issuances or convertible securities?

Clinical trials

13 days ago

Read more globenewswire